Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Tirzepatide, Semaglutide and Gut Bacteria

A 36-person OMDOT-1 analysis found exploratory gut microbiome changes with tirzepatide and semaglutide, without proving a clinical benefit.

Why we wrote this. Microbiome findings can sound more clinical than they are, so we separated measured bacterial patterns from predicted functions and patient outcomes.

In this article (6 sections)
  1. The analysis followed stool samples over 16 weeks
  2. Overall community structure did not separate the groups
  3. Predicted functions were similar across both medicines
  4. Weight loss and glucose change remain possible explanations
  5. What we don't yet know
  6. What this means for patients

A 16-week exploratory analysis found different gut-bacteria patterns during treatment with tirzepatide and semaglutide, but it did not show that either medicine improves gut health. The study included 36 people with type 2 diabetes from the randomized OMDOT-1 trial. Researchers collected stool at five time points and used 16S rRNA sequencing to track bacterial groups[1].

The clearest negative result came first: overall between-group beta diversity did not differ significantly. Alpha diversity rose mainly in the tirzepatide group, while several individual genera followed different trajectories compared with conventional treatment. Those findings are exploratory associations from a small secondary analysis, not evidence that microbiome change explains weight loss or glucose improvement[2].

The analysis followed stool samples over 16 weeks

OMDOT-1 compared tirzepatide, semaglutide and conventional treatment in people with type 2 diabetes. This secondary paper studied 36 trial participants rather than reporting the full trial's clinical outcomes. Samples were collected at five time points. The laboratory used 16S rRNA gene sequencing, which identifies bacterial lineages from a marker gene but does not directly measure the complete genes or activity of every organism[1].

Researchers screened genus-level patterns with MaAsLin2, then evaluated candidate genera in longitudinal mixed-effects models. Their main models adjusted for baseline body mass index. Sensitivity analyses also adjusted for changes in body weight and HbA1c. That extra adjustment asks whether the microbiome signals persist after accounting for two major metabolic changes, but it cannot prove what caused any bacterial shift[2].

Random assignment in the parent trial strengthens the treatment comparison. It does not remove the limits created by a 36-person microbiome subset, many tested bacterial groups and an exploratory analysis that was not the parent trial's main question.

Overall community structure did not separate the groups

Beta diversity asks whether the overall composition of microbial communities differs between groups. The investigators found no significant between-group beta-diversity difference. Alpha diversity, a within-sample measure of variety, increased predominantly with tirzepatide and showed a significant time-by-treatment interaction against conventional treatment[1]. Diversity is a descriptive microbiome measure. A higher value is not automatically healthier, and this paper did not test whether the change improved symptoms or prevented complications.

Several genera followed treatment-associated trajectories. Romboutsia_B, Barnesiella and Ruminococcus_E differed from control with both medicines, while Vescimonas differed with tirzepatide. The reported false-discovery-rate threshold was q below 0.05[2]. Genus labels do not tell us which strains changed, what those strains were doing or whether the difference helped patients.

Predicted functions were similar across both medicines

The team used PICRUSt2 to infer microbial functions from the 16S profiles. Across 2,106 predicted enzyme-commission features, tirzepatide and semaglutide effects pointed in the same direction 67.1% of the time. The correlation was moderate (Pearson r = 0.450, p below 0.001). Treatment-versus-control comparisons identified predicted changes involving energy and carbohydrate metabolism[1].

Predicted function is not measured function. PICRUSt2 estimates which genes might be present by comparing marker-gene profiles with reference genomes. It does not show that those genes were active, that microbial metabolites changed or that a predicted pathway affected a participant. The authors describe these results as distinct from a separate week-16 shotgun-metagenomic endpoint analysis.

Weight loss and glucose change remain possible explanations

GLP-1-based medicines change appetite, food intake, body weight and glycaemia. Each could alter the gut environment without a direct drug effect on bacteria. The sensitivity models adjusted for changes in weight and HbA1c, yet adjustment in a small dataset cannot fully separate treatment, diet and metabolic response. The PubMed abstract does not report dietary intake, antibiotic exposure, group sizes, attrition or adverse events for this microbiome subset[2].

The analysis also tested many taxonomic and predicted functional outcomes. False-discovery-rate correction reduces false positives, but it cannot make an exploratory signal confirmatory. Replication in larger trials with measured diet, medication exposure, shotgun sequencing and metabolite assays would be needed before assigning a biological mechanism.

What we don't yet know

We do not know whether these patterns last beyond 16 weeks. We do not know whether the named genera mediate weight loss, glucose control or side effects. The study does not establish a healthy target microbiome for people taking either medicine. Its abstract does not provide enough detail to judge subgroup balance, missing-sample handling, funding or author conflicts. The indexed record should therefore be read as an exploratory map for later work, not a clinical decision tool.

What this means for patients

This paper offers no basis for choosing tirzepatide over semaglutide, adding a probiotic or changing food intake to chase one bacterial genus. Treatment decisions still depend on approved indications, contraindications, tolerability, access and a clinician's assessment. The microbiome findings may help researchers design better mechanistic studies. They do not establish a patient-facing intervention.

Readers comparing the medicines can use our tirzepatide evidence overview and semaglutide regulation summary for broader context. Neither page turns this secondary analysis into dosing or diet guidance.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Did tirzepatide improve the gut microbiome?

The study found increased alpha diversity mainly with tirzepatide and changes in several bacterial genera. It did not define a healthy microbiome or show that those changes improved symptoms, weight loss, glucose control or any other patient outcome.

Was tirzepatide better than semaglutide in this analysis?

No clinical comparison can be made from this paper. Some taxonomic patterns differed, while predicted functional effects were broadly similar. The analysis was exploratory, included 36 participants and was not designed to decide which medicine works better for a patient.

What does predicted microbial function mean?

PICRUSt2 estimates potential microbial genes from 16S marker-gene data and reference genomes. It does not directly measure gene activity, metabolites or effects on a person's health. Functional predictions need confirmation with direct molecular measurements.

Should patients change their diet or take probiotics because of this study?

The paper does not test a diet or probiotic intervention and does not identify a microbiome target for patients. Anyone considering changes alongside prescription treatment should discuss them with a qualified healthcare professional who knows their medical history.

Sources

  1. [1]OMDOT-1 exploratory gut microbiome analysis, PubMed PMID 43000189Tier 1 · primary↩
  2. [2]OMDOT-1 microbiome analysis, NCBI structured abstract recordTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars